vTv Therapeutics (VTVT) Q2 2025 earnings summary

Executive summary

• Focused on developing oral, small molecule drug candidates for diabetes and chronic diseases, with lead candidate cadisegliatin in Phase 3 for type 1 diabetes.

• First participant randomized in Phase 3 CATT1 trial for cadisegliatin; top-line data expected in H2 2026.

• Expanded intellectual property with new patent claims and allowance for crystalline salt form of cadisegliatin, extending protection to 2041.

• Appointed new CFO, Michael Tung, in May 2025.

Financial highlights

• Net loss attributable to common shareholders was $6.0M ($0.92 per share) for Q2 2025, compared to $5.2M ($0.81 per share) in Q2 2024.

• Net loss for the six months ended June 30, 2025 was $11.1M, up from $10.0M for the same period in 2024.

• No revenue recognized in Q2 2025; $1.0M milestone revenue recognized in H1 2024.

• Cash and cash equivalents were $25.9M as of June 30, 2025, down from $36.7M at December 31, 2024.

• R&D expenses rose to $4.1M in Q2 2025 (up 19% YoY), mainly due to higher payroll costs.

Outlook and guidance

• Expects continued significant R&D expenses as clinical programs advance.

• Top-line data from CATT1 Phase 3 trial anticipated in H2 2026; additional registrational studies planned for 2027.

• Evaluating financing strategies, including equity investments and licensing, to increase cash reserves.

• Forward-looking statements caution about risks and uncertainties, including clinical trial timing and regulatory outcomes.